Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment–Health Professional Version (PDQ®)

SECTIONS

Changes to This Summary (04/05/2016)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Treatment of Newly Diagnosed AML

Added text about the Children's Oncology Group AAML03P1 and AAML0531 trials that examined incorporation of the anti-CD33 conjugated antibody gemtuzumab ozogamicin into induction therapy (cited Gamis et al. as reference 20 and Pollard et al. as reference 21 and level of evidence 1iiD).

Juvenile Myelomonocytic Leukemia

Added text about LIN28B overexpression and the correlation with poor prognosic factors (cited Helsmoortel et al. as reference 22).

Chronic Myelogenous Leukemia

The Treatment of CML in Adults with TKIs subsection was extensively revised.

The Treatment of CML in Children subsection was extensively revised.

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Survivorship and Adverse Late Sequelae

Next section >
About This PDQ Summary